- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05479591
A Research Study Looking at Blood Sugar Control in People With Type 2 Diabetes Previously Treated With Premix Insulin and Initiating Treatment With Insulin Degludec/Liraglutide (IDegLira) in Local Clinical Practice in Croatia (GLIDE)
October 28, 2022 updated by: Novo Nordisk A/S
Glycaemic Control and Management in Adult Type 2 Diabetes Patients Previously Treated With Premix Insulins and Initiating Treatment With IDegLira in Routine Clinical Practice in Croatia: A 36-week Single Arm, Prospective, Multi-centre, Non-interventional Study
The purpose of this study is to look at the blood sugar control in participants with type 2 diabetes previously treated with premix insulins and initiating treatment with IDegLira.
Participants will get IDegLira as prescribed by study doctor regardless of participant's decision to participate in the study.
Decision to initiate treatment with IDegLira will be made by study doctor independent from the study.
The study will last for about 36 weeks.
Participants will be asked questions about their health and diabetes treatment and lab tests as part of their normal doctor's appointment.
Study Overview
Study Type
Observational
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Participants with Type 2 Diabetes.
Description
Inclusion Criteria:
- Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
- Male or female patients aged greater than or equal to (>=) 18 years at the time of signing informed consent.
- Patients diagnosed with T2D and receiving treatment with premix insulin for at least 12 weeks (3 months) based on local clinical guidelines.
- Switched to treatment with IDegLira from previous treatment of premix insulins. The decision to initiate treatment with IDegLira must be independently from the decision to enrol in the study.
- Available and documented HbA1c collected within 12 weeks prior to initiation of IDegLira.
Exclusion Criteria:
- Previous participation in this study. Participation is defined as having given informed consent in this study.
- Participation in any other T2D clinical trial of an approved or non-approved investigational medicinal product within 30 days prior to initiation of IDegLira.
- Previous treatment with IDegLira.
- Patients diagnosed with Type 1 diabetes mellitus.
- Female who is known to be pregnant, breastfeeding or intends to become pregnant during the conduct of the study.
- Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
- Known or suspected hypersensitivity to the active substance or to any of the excipients as specified in the IDegLira label in Croatia.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Participants with type 2 diabetes (T2D)
Participants with T2D previously treated with premix insulin for at least 12 weeks (3 months) based on local clinical guidelines will initiate treatment with IDegLira at the treating physician's discretion according to the approved IDegLira label in Croatia.
|
Participants will be treated with IDegLira at the treating physician's discretion according to the approved IDegLira label in Croatia and independent from the decision to include the participant in the study.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Glycated Haemoglobin A1c (HbA1c)
Time Frame: From baseline to end of study (week 36 ± 6 weeks)
|
Measured in percentage (%) point.
|
From baseline to end of study (week 36 ± 6 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with HbA1c less than (<) 7.0%
Time Frame: At end of study (week 36 ± 6 weeks)
|
Number of participants having Yes/No.
|
At end of study (week 36 ± 6 weeks)
|
Starting dose of IDegLira
Time Frame: At baseline
|
Measured in dose steps/day.
|
At baseline
|
Dose of IDegLira at end of study
Time Frame: At end of study (week 36 ± 6 weeks)
|
Measured in dose steps/day.
|
At end of study (week 36 ± 6 weeks)
|
Change in body weight
Time Frame: From baseline to end of study (week 36 ± 6 weeks)
|
Measured in kilograms (kg).
|
From baseline to end of study (week 36 ± 6 weeks)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
July 30, 2022
Primary Completion (Anticipated)
April 30, 2023
Study Completion (Anticipated)
April 30, 2023
Study Registration Dates
First Submitted
July 27, 2022
First Submitted That Met QC Criteria
July 27, 2022
First Posted (Actual)
July 29, 2022
Study Record Updates
Last Update Posted (Actual)
November 1, 2022
Last Update Submitted That Met QC Criteria
October 28, 2022
Last Verified
October 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NN9068-4972
- U1111-1271-8967 (Other Identifier: World Health Organization (WHO))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
AstraZenecaRecruiting
Clinical Trials on IDegLira
-
Novo Nordisk A/SCompleted
-
Novo Nordisk A/SCompleted
-
Stefano RizzaCompleted
-
Novo Nordisk A/SNot yet recruiting
-
University of Campania "Luigi Vanvitelli"Completed
-
Novo Nordisk A/SCompleted
-
Xiangya Hospital of Central South UniversityRecruitingType 2 Diabetes MellitusChina
-
Hospital Universitario San IgnacioRecruitingDiabetes Mellitus, Type 2 Treated With InsulinColombia
-
Population Health Research InstituteNovo Nordisk A/SCompletedType 2 Diabetes MellitusCanada